» Articles » PMID: 38169635

P32 Regulates Glycometabolism and TCA Cycle to Inhibit CcRCC Progression Via Copper-induced DLAT Lipoylation Oligomerization

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2024 Jan 3
PMID 38169635
Authors
Affiliations
Soon will be listed here.
Abstract

A key player in mitochondrial respiration, p32, often referred to as C1QBP, is mostly found in the mitochondrial matrix. Previously, we showed that p32 interacts with DLAT in the mitochondria. Here, we found that p32 expression was reduced in ccRCC and suppressed progression and metastasis in ccRCC animal models. We observed that increasing p32 expression led to an increase in oxidative phosphorylation by interacting with DLAT, thus, regulating the activation of the pyruvate dehydrogenase complex (PDHc). Mechanistically, reduced p32 expression, in concert with DLAT, suppresses PDHc activity and the TCA cycle. Furthermore, our research discovered that p32 has a direct binding affinity for copper, facilitating the copper-induced oligomerization of lipo-DLAT specifically in ccRCC cells. This finding reveals an innovative function of the p32/DLAT/copper complex in regulating glycometabolism and the TCA cycle in ccRCC. Importantly, our research provides important new understandings of the underlying molecular processes causing the abnormal mitochondrial metabolism linked to this cancer.

Citing Articles

Activation of PI3K-AKT pathway prevents steroid-induced osteonecrosis of the femoral head via inhibiting Cuproptosis.

Gao S, Zhu H, Chen H, Lu H, Wen M, Fan Y Sci Rep. 2025; 15(1):8950.

PMID: 40089548 DOI: 10.1038/s41598-025-93555-8.


Metabolic shifts in lipid utilization and reciprocal interactions within the lung metastatic niche of triple-negative breast cancer revealed by spatial multi-omics.

Kan J, Lee H, Hou M, Tsai H, Jian S, Chang C Cell Death Dis. 2024; 15(12):899.

PMID: 39695088 PMC: 11655832. DOI: 10.1038/s41419-024-07205-4.


Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives.

Zhang C, Huang T, Li L J Hematol Oncol. 2024; 17(1):68.

PMID: 39152464 PMC: 11328505. DOI: 10.1186/s13045-024-01589-8.

References
1.
Borger D, Tanabe K, Fan K, Lopez H, Fantin V, Straley K . Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist. 2011; 17(1):72-9. PMC: 3267826. DOI: 10.1634/theoncologist.2011-0386. View

2.
Vyas S, Zaganjor E, Haigis M . Mitochondria and Cancer. Cell. 2016; 166(3):555-566. PMC: 5036969. DOI: 10.1016/j.cell.2016.07.002. View

3.
Park S, Jeon J, Min B, Ha C, Thoudam T, Park B . Role of the Pyruvate Dehydrogenase Complex in Metabolic Remodeling: Differential Pyruvate Dehydrogenase Complex Functions in Metabolism. Diabetes Metab J. 2018; 42(4):270-281. PMC: 6107359. DOI: 10.4093/dmj.2018.0101. View

4.
Cohen A, Holmen S, Colman H . IDH1 and IDH2 mutations in gliomas. Curr Neurol Neurosci Rep. 2013; 13(5):345. PMC: 4109985. DOI: 10.1007/s11910-013-0345-4. View

5.
Gerosa C, Fanni D, Congiu T, Piras M, Cau F, Moi M . Liver pathology in Wilson's disease: From copper overload to cirrhosis. J Inorg Biochem. 2019; 193:106-111. DOI: 10.1016/j.jinorgbio.2019.01.008. View